^
    1year
    Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? An excellent review👇 https://t.co/WEdbZlHexv (@dr_yakupergun)
    Review
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    over1year
    Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy. #bcsm #SABCS22 | @UTHealthSAMDA @VKaklamani https://t.co/Y6ujtNYpQx (@TargetedOnc)
    Clinical • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Orserdu (elacestrant)
    over1year
    Earlier this week, @VKaklamani, MD, leader of the @UTHealthSAMDA breast cancer program & co-director of the @SABCSSanAntonio, presented the Phase III results of the EMERALD trial evaluating a novel oral drug therapy for metastatic ER-positive/HER2-negative breast cancer. #SABCS22 (@UTHealthSAMDA)
    Clinical • P3 data
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
    over1year
    Why Black Race breast cancer patients do worse for er positive and her2 negative pt outcome ? Do they have different biology? @SABCSSanAntonio @OncoAlert #sabcs22 (@SuyogCancer)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    over1year
    PD13-01 Thursday @SABCSSanAntonio Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial Presenter: @vidalmar80 (@prat_aleix)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    Orserdu (elacestrant)
    almost2years
    NICE approves two treatment options for advanced breast cancer https://t.co/MraoHvwr6i Alpelisib first targeted treatment for patients with PIK3CA mutation found in 30-40% of oestrogen receptor positive HER2 negative breast cancers @DrIanWeissman @SusanChubb1 @SirGeoffPalmer (@Nigelj08223326)
    Clinical • NICE
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • ER positive + HER-2 negative
    |
    Piqray (alpelisib)
    2years
    Dr. Sofia Mastoraki shares a novel prognostic tool that may help identify patients with early-stage ER positive/HER2 negative breast cancer that will benefit from long-term endocrine therapy: https://t.co/9hZlofDXuX @SofiaMast1 @KellyKhunt @kandymarsy #AACR22 #EndCancer (@MDAndersonNews)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
    over2years
    Promising anti-tumour activity of the CDK7-inhibitor samuraciclib (plus fulvestrant) in pre-treated ER-positive/HER2-negative metastatic breast cancer https://t.co/ZkTvQKcUsP (@MaglioccoTony)
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    samuraciclib (CT7001)
    almost3years
    Acceptability of a patient decision aid for women aged 70 and older with stage I, estrogen receptor-positive, HER2-negative breast cancer https://t.co/uy54KJ9Tee @rochgerionc @WilliamDale_MD @SIOGorg @myCARG @MySuppCareCOH #GeriOnc #breastcancer (@JGeriOnc)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    3years
    TAK-228 Plus Hormonal Therapy for Metastatic, ER-Positive/HER2-Negative Breast Cancer https://t.co/pL4ju5rEGW via @practiceupdate (@naborala)
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    sapanisertib (CB-228)